Biogen leverages their knowledge of pathophysiological processes and disease characteristics to pioneer new potential treatments. Biogen R&D is driven by the potential to transform the lives of patients. They work in disease areas with some of the greatest unmet needs.

Biogen’s medicine aims to improve the well-being of people around the world. Biogen has been successfully manufacturing large molecule therapies for over two decades, and they take their responsibility of making and delivering quality medicine very seriously. In recent years, they have extended their expertise into the production of small molecule therapies and have fully integrated an oral solid dose facility into their manufacturing infrastructure.

Biogen attributes its success to excellence in several key areas. Their process development team continually advances our understanding of the biology and process technology that are both critical to improving our capabilities and output. Their advanced engineering teams ensure their manufacturing plants are state-of-the-art and equipped with cutting-edge technologies to meet the demand for their existing therapies, clinical trials and opportunities in biosimilars. Biogen’s world-class manufacturing teams are vital to the efficient and reliable operation of these assets. Their quality team manages compliance and supervises consistent and dependable production of our therapies, while their supply chain group works to make sure Biogen can get their therapies to patients when and where they need them. Thorough business continuity planning provides redundancy on a global level to ensure product availability. In addition, our teams create systems that reduce our impact on the environment by limiting waste and using resources efficiently. The combination of these skills enable us to manufacture and supply medicines to patients in more than 90 countries.